TELA Bio (NASDAQ:TELA) Price Target Lowered to $2.00 at Canaccord Genuity Group

TELA Bio (NASDAQ:TELA) had its price objective lowered by Canaccord Genuity Group from $4.00 to $2.00 in a research note released on Wednesday morning,Benzinga reports. The firm currently has a buy rating on the stock.

Other equities analysts have also recently issued research reports about the stock. Lake Street Capital reaffirmed a “buy” rating on shares of TELA Bio in a research report on Monday, December 1st. Weiss Ratings reissued a “sell (e+)” rating on shares of TELA Bio in a research report on Thursday, January 22nd. Finally, Loop Capital set a $3.00 price target on TELA Bio in a research note on Monday, December 1st. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, TELA Bio has an average rating of “Hold” and a consensus price target of $2.60.

TELA Bio Stock Down 9.4%

Shares of TELA opened at $0.69 on Wednesday. The firm has a market cap of $27.84 million, a P/E ratio of -0.83 and a beta of 0.88. TELA Bio has a 12-month low of $0.62 and a 12-month high of $2.20. The company’s 50-day moving average price is $0.85 and its 200 day moving average price is $1.14. The company has a current ratio of 3.30, a quick ratio of 2.62 and a debt-to-equity ratio of 26.65.

TELA Bio (NASDAQ:TELA) last announced its earnings results on Tuesday, March 24th. The company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.18) by $0.02. TELA Bio had a negative net margin of 48.37% and a negative return on equity of 396.31%. The company had revenue of $20.87 million during the quarter, compared to analyst estimates of $21.04 million. On average, sell-side analysts forecast that TELA Bio will post -1.37 earnings per share for the current year.

Institutional Trading of TELA Bio

A number of large investors have recently made changes to their positions in the company. WealthTrust Axiom LLC acquired a new stake in TELA Bio in the second quarter valued at approximately $40,000. XTX Topco Ltd acquired a new stake in shares of TELA Bio in the 4th quarter valued at $48,000. Citadel Advisors LLC raised its holdings in shares of TELA Bio by 161.3% in the 3rd quarter. Citadel Advisors LLC now owns 35,281 shares of the company’s stock valued at $53,000 after purchasing an additional 21,781 shares in the last quarter. Susquehanna International Group LLP grew its stake in shares of TELA Bio by 551.2% during the third quarter. Susquehanna International Group LLP now owns 85,763 shares of the company’s stock worth $128,000 after purchasing an additional 72,594 shares in the last quarter. Finally, Embree Financial Group increased its holdings in TELA Bio by 695.1% in the fourth quarter. Embree Financial Group now owns 111,318 shares of the company’s stock valued at $131,000 after buying an additional 97,318 shares during the last quarter. 94.35% of the stock is currently owned by hedge funds and other institutional investors.

More TELA Bio News

Here are the key news stories impacting TELA Bio this week:

• Positive Sentiment: Q4 EPS slightly beat estimates: TELA reported GAAP EPS around ($0.16), modestly better than consensus (~$0.18) — a small beat that can be seen as stabilizing after prior losses. Earnings release & transcript
• Positive Sentiment: Management targets growth in 2026: the company is guiding to at least ~8% revenue growth for 2026 while pursuing a commercial transformation — a constructive forward signal if execution holds. Guidance article
• Positive Sentiment: Some analysts remain bullish: Lake Street and Canaccord kept buy ratings (while lowering price targets to $2.00), signaling continued upside expectations from certain brokerages. Canaccord/Lake Street note
• Neutral Sentiment: Revenue roughly in line / mixed read: Q4 revenue was $20.87M vs. consensus ~$21.04M — effectively flat to a slight miss, leaving mixed interpretation depending on margin trends and execution. Press release
• Neutral Sentiment: Readouts and call transcripts available: investors can review the full earnings release and multiple call transcripts for details on commercial initiatives and margin outlook. Earnings call transcript
• Neutral Sentiment: Trading activity is elevated: intraday volume is well above recent average — higher volume often amplifies price moves and reflects stronger investor attention (could be either direction).
• Negative Sentiment: Analysts cut forecasts / price-target trims: multiple firms adjusted models after the quarter — Piper Sandler cut its target to $1.00 and moved to Neutral; Benzinga and other coverage describe broader analyst downward revisions. This reduces near-term upside consensus. Analyst cuts article
• Negative Sentiment: Profitability & balance-sheet metrics remain challenging: the company still posts negative net margins and very high negative ROE; debt-to-equity and small market cap increase execution and volatility risk for investors. Zacks coverage
• Negative Sentiment: Short-interest reports show anomalous data: multiple notices flagged a “large increase” but reported zero/NaN figures — treat these data as unreliable until clarified; a true rise in short interest would be bearish.

About TELA Bio

TELA Bio, Inc (NASDAQ: TELA) is a commercial‐stage medical technology company headquartered in Malvern, Pennsylvania. The company is focused on developing, manufacturing and commercializing regenerative medicine and advanced soft tissue repair solutions. By integrating proprietary biomaterials and processing technologies, TELA Bio aims to offer products that support the body’s natural healing processes in wound closure, hernia repair, reconstructive surgery and other surgical specialties.

The company’s product portfolio includes acellular dermal matrices, hemostatic agents and tissue scaffold systems.